{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:47:11Z","timestamp":1787010431437,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Prevention of cytomegalovirus (CMV) infection after kidney transplantation is costly and burdensome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Given its promising utility in risk stratification, we evaluated the use of QuantiFERON-CMV (QFCMV) and additional clinical variables in this prospective cohort study to predict the first clinically significant CMV infection (CS-CMV, ranging from asymptomatic viremia requiring treatment to CMV disease) in the first posttransplant year. A cost-effectiveness analysis for guided prevention was done.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      One hundred adult kidney transplant recipients, CMV IgG\n                      <jats:sup>+<\/jats:sup>\n                      , were given basiliximab induction and maintained on steroid\/mycophenolate\/tacrolimus with weekly CMV monitoring. Thirty-nine patients developed CS-CMV infection (viral syndrome, n\u2009=\u20091; end-organ disease, n\u2009=\u20099; and asymptomatic viremia, n\u2009=\u200929). A nonreactive or indeterminate QFCMV result using the standard threshold around day 30 (but not before transplant) was associated with CS-CMV rates of 50% and 75%, respectively. A higher QFCMV threshold for reactivity (&gt;1.0 IU interferon-\u03b3\/mL) outperformed the manufacturer\u2019s standard (&gt;0.2 IU interferon-\u03b3\/mL) in predicting protection but still allowed a 16% incidence of CS-CMV. The combination of recipient age and type of donor, along with posttransplant QFCMV resulted in a prediction model that increased the negative predictive value from 84% (QFCMV alone) to 93%. QFCMV-guided preemptive therapy was of lower cost than preemptive therapy alone (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001, probabilistic sensitivity analysis) and was cost-effective (incremental net monetary benefit of 210 USD) assuming willingness-to-pay of 2000 USD to avoid 1 CMV disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Guided CMV prevention by the prediction model with QFCMV is cost-effective and would spare from CMV surveillance in 42% of patients with low risk for CS-CMV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000004870","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:01:09Z","timestamp":1700611269000},"page":"985-995","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["QuantiFERON-CMV as a Predictor of CMV Events During Preemptive Therapy in CMV-seropositive Kidney Transplant Recipients"],"prefix":"10.1097","volume":"108","author":[{"given":"Jos\u00e9 O.","family":"Reusing","sequence":"first","affiliation":[{"name":"Renal Transplant Service, Instituto Central, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Agena","sequence":"additional","affiliation":[{"name":"Renal Transplant Service, Instituto Central, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille N.","family":"Kotton","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Campana","sequence":"additional","affiliation":[{"name":"Medical Director Department, Dasa, Barueri, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia Camera","family":"Pierrotti","sequence":"additional","affiliation":[{"name":"Medical Director Department, Dasa, Barueri, Brazil."},{"name":"Division of Infectious Disease, Faculdade de Medicina, Universidade de S\u00e3o Paulo, Sao Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"David-Neto","sequence":"additional","affiliation":[{"name":"Renal Transplant Service, Instituto Central, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"e12732","DOI":"10.1111\/tid.12732","article-title":"Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting.","volume":"19","author":"Hakimi","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"e13483","DOI":"10.1111\/tid.13483","article-title":"Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: a systematic literature review of real-world evidence.","volume":"23","author":"Raval","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"Suppl 4","key":"R3-20250604","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation.","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"R4-20250604","first-page":"CD005133","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.","volume":"2013","author":"Owers","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/tri.12629","article-title":"Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?","volume":"28","author":"Fehr","year":"2015","journal-title":"Transpl Int"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant.","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/TP.0000000000000189","article-title":"A double-blinded, prospective study to define antigenemia and quantitative real-time polymerase chain reaction cutoffs to start preemptive therapy in low-risk, seropositive, renal transplanted recipients.","volume":"98","author":"David-Neto","year":"2014","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11908-018-0610-4","article-title":"Immune monitoring for CMV in transplantation.","volume":"20","author":"Yong","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/ajt.17147","article-title":"A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients.","volume":"22","author":"Azar","year":"2022","journal-title":"Am J Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials.","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"ofy230","DOI":"10.1093\/ofid\/ofy230","article-title":"Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation.","volume":"5","author":"Meesing","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1038\/cti.2014.3","article-title":"Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation.","volume":"3","author":"Fern\u00e1ndez-Ruiz","year":"2014","journal-title":"Clin Transl Immunology"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"e12929","DOI":"10.1111\/tid.12929","article-title":"Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: outcome and risk factors for late CMV disease.","volume":"20","author":"Reusing","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0002-9394(14)70381-2","article-title":"Cytomegalovirus antigenemia in acquired immunodeficiency syndrome patients with untreated cytomegalovirus retinitis.","volume":"122","author":"Pannuti","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.09.017","article-title":"Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection.","volume":"56","author":"Mart\u00edn-Gandul","year":"2013","journal-title":"J Clin Virol"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-\u03b3 secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation.","volume":"13","author":"Cantis\u00e1n","year":"2013","journal-title":"Am J Transplant"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"h3868","DOI":"10.1136\/bmj.h3868","article-title":"How to develop a more accurate risk prediction model when there are few events.","volume":"351","author":"Pavlou","year":"2015","journal-title":"BMJ"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/TP.0b013e318200000c","article-title":"Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.","volume":"91","author":"Luan","year":"2011","journal-title":"Transplantation"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5935\/0101-2800.20170074","article-title":"The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxis.","volume":"39","author":"Felipe","year":"2017","journal-title":"J Bras Nefrol"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/ajt.15875","article-title":"CMV immune monitoring\u2014where do we go from here?","volume":"20","author":"Kumar","year":"2020","journal-title":"Am J Transplant"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients.","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/tri.12848","article-title":"Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.","volume":"29","author":"Cervera","year":"2016","journal-title":"Transpl Int"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"112831","DOI":"10.1016\/j.jim.2020.112831","article-title":"The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for detection of neoantigen-specific T cells in PBMC.","volume":"484-485","author":"Tang","year":"2020","journal-title":"J Immunol Methods"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcv.2012.02.020","article-title":"Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation.","volume":"54","author":"Emery","year":"2012","journal-title":"J Clin Virol"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.","volume":"51","author":"Abate","year":"2013","journal-title":"J Clin Microbiol"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1097\/TP.0000000000002421","article-title":"CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+\/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy.","volume":"102","author":"Jarque","year":"2018","journal-title":"Transplantation"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1038\/s41598-020-64133-x","article-title":"Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact.","volume":"10","author":"Valle-Arroyo","year":"2020","journal-title":"Sci Rep"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation.","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial.","volume":"74","author":"P\u00e1ez-Vega","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation.","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"e15228","DOI":"10.1097\/MD.0000000000015228","article-title":"Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: a PRISMA-compliant article.","volume":"98","author":"Ruan","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.","volume":"105","author":"Gliga","year":"2018","journal-title":"J Clin Virol"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/ajt.15793","article-title":"Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-\u03b3 release assay in kidney transplant recipients treated with antithymocyte globulin.","volume":"20","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Am J Transplant"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/lt.24216","article-title":"Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation.","volume":"21","author":"Sood","year":"2015","journal-title":"Liver Transpl"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/cid\/ciz1209","article-title":"Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional, multicenter clinical trial.","volume":"71","author":"Jarque","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"381.e1","DOI":"10.1016\/j.cmi.2018.05.010","article-title":"Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.","volume":"25","author":"Fern\u00e1ndez-Ruiz","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/diagnostics11050875","article-title":"Utility of CMV-specific immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update.","volume":"11","author":"Prakash","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.nefro.2016.11.018","article-title":"Cytomegalovirus infection after kidney transplantation and long-term graft loss.","volume":"37","author":"L\u00f3pez-Oliva","year":"2017","journal-title":"Nefrologia"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/tri.12586","article-title":"Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.","volume":"28","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Transpl Int"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.transproceed.2013.07.070","article-title":"Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients.","volume":"46","author":"D\u00edaz","year":"2014","journal-title":"Transplant Proc"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/tid.12494","article-title":"Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.","volume":"18","author":"Radtke","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10096-019-03744-3","article-title":"Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.","volume":"39","author":"Hemmersbach-Miller","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiz194","article-title":"Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.","volume":"220","author":"Kaminski","year":"2019","journal-title":"J Infect Dis"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"e13516","DOI":"10.1111\/ctr.13516","article-title":"Infections after kidney transplantation. Does age matter?","volume":"33","author":"Hemmersbach-Miller","year":"2019","journal-title":"Clin Transplant"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/j.1600-6143.2005.00912.x","article-title":"Renal ischemia\/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter.","volume":"5","author":"Kim","year":"2005","journal-title":"Am J Transplant"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3389\/fimmu.2018.01716","article-title":"Predicting antigen presentation-what could we learn from a million peptides?","volume":"9","author":"Gfeller","year":"2018","journal-title":"Front Immunol"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/phar.1774","article-title":"Single-dose basiliximab induction in low-risk renal transplant recipients.","volume":"36","author":"Cunningham","year":"2016","journal-title":"Pharmacotherapy"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003495-199957020-00006","article-title":"Basiliximab.","volume":"57","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"R54-20250604","first-page":"CD003897","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients.","volume":"2010","author":"Webster","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: a bad idea.","volume":"25","author":"Royston","year":"2006","journal-title":"Stat Med"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"e00257","DOI":"10.1128\/JVI.00257-19","article-title":"Interferon gamma inhibits Varicella-Zoster virus replication in a cell line-dependent manner.","volume":"93","author":"Shakya","year":"2019","journal-title":"J Virol"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"e0171621","DOI":"10.1128\/jcm.01716-21","article-title":"Utility of cytomegalovirus cell-mediated immunity assays in solid organ transplantation.","volume":"60","author":"Hall","year":"2022","journal-title":"J Clin Microbiol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:08:56Z","timestamp":1749046136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004870","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}